Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature
Lenalidomide is indicated in the front-line management of multiple myeloma. More recently, it has been introduced for use in treating other hematologic malignancies. Although the drug is known to cause myelosuppression, there have been rare reports of lenalidomide-associated immune thrombocytopenia...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2020/8825618 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550868804698112 |
|---|---|
| author | William Forehand III Germame Ajebo Michael Toscano Anand Jillella Paul Dainer |
| author_facet | William Forehand III Germame Ajebo Michael Toscano Anand Jillella Paul Dainer |
| author_sort | William Forehand III |
| collection | DOAJ |
| description | Lenalidomide is indicated in the front-line management of multiple myeloma. More recently, it has been introduced for use in treating other hematologic malignancies. Although the drug is known to cause myelosuppression, there have been rare reports of lenalidomide-associated immune thrombocytopenia (ITP). Here, we review the literature on lenalidomide-associated ITP and report upon a 59-year-old man who was administered lenalidomide due to concern of progressive multiple myeloma more than a year following his having undergone an autologous hematopoietic stem cell transplant. His platelet count precipitously declined and lead to his hospitalization. Despite our withholding of the drug, he did not respond to platelet transfusions or administration of corticosteroids. He was successfully managed with intermittent immune globulin for several months before definitive treatment with splenectomy, which resulted in the complete resolution of his thrombocytopenia. A literature search identified a total of six additional cases of lenalidomide-associated ITP. Similarly, many of the reported cases were associated with persistent thrombocytopenia after discontinuation of the drug. Furthermore, these patients were generally managed successfully with standard ITP therapies, such as corticosteroids or intravenous immune globulin. |
| format | Article |
| id | doaj-art-dc628806275341a5bcba4604fd90df2a |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-dc628806275341a5bcba4604fd90df2a2025-02-03T06:05:39ZengWileyCase Reports in Hematology2090-65602090-65792020-01-01202010.1155/2020/88256188825618Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the LiteratureWilliam Forehand III0Germame Ajebo1Michael Toscano2Anand Jillella3Paul Dainer4Division of Hematology-Oncology, Medical College of Georgia, Augusta University, Georgia Cancer Center, Augusta, GeorgiaDivision of Hematology-Oncology, Medical College of Georgia, Augusta University, Georgia Cancer Center, Augusta, GeorgiaDepartment of Pathology and Laboratory Medicine, Augusta University, Augusta, GeorgiaDivision of Hematology-Oncology, Medical College of Georgia, Augusta University, Georgia Cancer Center, Augusta, GeorgiaDivision of Hematology-Oncology, Medical College of Georgia, Augusta University, Georgia Cancer Center, Augusta, GeorgiaLenalidomide is indicated in the front-line management of multiple myeloma. More recently, it has been introduced for use in treating other hematologic malignancies. Although the drug is known to cause myelosuppression, there have been rare reports of lenalidomide-associated immune thrombocytopenia (ITP). Here, we review the literature on lenalidomide-associated ITP and report upon a 59-year-old man who was administered lenalidomide due to concern of progressive multiple myeloma more than a year following his having undergone an autologous hematopoietic stem cell transplant. His platelet count precipitously declined and lead to his hospitalization. Despite our withholding of the drug, he did not respond to platelet transfusions or administration of corticosteroids. He was successfully managed with intermittent immune globulin for several months before definitive treatment with splenectomy, which resulted in the complete resolution of his thrombocytopenia. A literature search identified a total of six additional cases of lenalidomide-associated ITP. Similarly, many of the reported cases were associated with persistent thrombocytopenia after discontinuation of the drug. Furthermore, these patients were generally managed successfully with standard ITP therapies, such as corticosteroids or intravenous immune globulin.http://dx.doi.org/10.1155/2020/8825618 |
| spellingShingle | William Forehand III Germame Ajebo Michael Toscano Anand Jillella Paul Dainer Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature Case Reports in Hematology |
| title | Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature |
| title_full | Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature |
| title_fullStr | Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature |
| title_full_unstemmed | Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature |
| title_short | Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature |
| title_sort | lenalidomide associated immune thrombocytopenia a case report and review of the literature |
| url | http://dx.doi.org/10.1155/2020/8825618 |
| work_keys_str_mv | AT williamforehandiii lenalidomideassociatedimmunethrombocytopeniaacasereportandreviewoftheliterature AT germameajebo lenalidomideassociatedimmunethrombocytopeniaacasereportandreviewoftheliterature AT michaeltoscano lenalidomideassociatedimmunethrombocytopeniaacasereportandreviewoftheliterature AT anandjillella lenalidomideassociatedimmunethrombocytopeniaacasereportandreviewoftheliterature AT pauldainer lenalidomideassociatedimmunethrombocytopeniaacasereportandreviewoftheliterature |